Median Technologies Partners with Tempus to Scale Lung Cancer AI Software in U.S.
Event summary
- Median Technologies signed a non-exclusive distribution agreement with Tempus AI to expand access to eyonis® LCS in the U.S.
- eyonis® LCS received FDA 510(k) clearance on February 9, 2026, with 93.3% sensitivity and 92.4% specificity in lung cancer screening.
- Tempus AI will distribute eyonis® LCS through its Tempus Pixel platform, supporting implementation and workflow integration.
- The collaboration targets 14.5 million Americans eligible for lung cancer screening, with revenue sharing between the parties.
The big picture
This partnership aligns with the growing trend of AI-driven precision medicine, leveraging Tempus AI's data-technology ecosystem to enhance early cancer detection. The collaboration positions Median to capitalize on the $601–$700 NT-APC 1508 reimbursement pathway, addressing a significant unmet need in lung cancer screening. The strategic move underscores the increasing convergence of AI and radiology in improving diagnostic accuracy and efficiency.
What we're watching
- Regulatory Progress
- Whether Median can secure CE marking for eyonis® LCS in Q2 2026, enabling European commercial rollout.
- Market Penetration
- The pace at which Tempus AI integrates eyonis® LCS into its Pixel platform and expands U.S. adoption.
- Revenue Impact
- How revenue sharing under the agreement affects Median's financial performance.
Related topics